Abstract:Glycoprotein, which has glycan branches on its protein surface, is one of major forms of proteins existing in human body [1]. Its sugar composition and branched structure are known to be very specific to differentiation stages or pathologic changes of cell [1]. Therefore, as a glycoprotein-based biomarkers (glyco-biomarkers), it has been already used as laboratory tests like hemoglobin A1c for blood glucose monitoring or carbohydrate-deficient transferrin for chronic alcohol consumption [1, 2]. A new glycobiomarker named Mac-2 binding protein glycosylation isomer (M2BPGi, Wisteria floribunda agglutinin-positive Mac-2 binding protein) is emerging as a serum marker for liver fibrosis. Liver fibrosis results from sustained hepatic injury and is characterized by excessive accumulation of fibrotic tissue and distortion of the normal hepatic architecture [3, 4]. Fibrotic change is originally considered irreversible; however, liver fibrosis regression or restoration of the functional capacity can be achieved by controlling hepatic damage with some antiviral agents [3, 4]. Therefore, the extent and degree of liver fibrosis can provide important prognostic information on patient outcomes [4]. For assessing liver fibrosis, conventional liver biopsy still remains the gold standard method [5]. However, due to its invasiveness and discomfort for patients, liver biopsy cannot be performed frequently [4]. In addition, various non-invasive scoring systems using elastographic methods or serum markers have been proposed as surrogate tools [3]. Among serum biomarkers for liver fibrosis, M2BPGi, has been recently introduced in laboratories as a commercially available form. Many clinical and laboratory data have been accumulated to show that M2BPGi can be a useful serum marker for evaluating liver fibrosis in various chronic liver diseases such as chronic hepatitis C virus infection, autoimmune hepatitis, primary biliary cholangitis, and non-alcoholic fatty liver disease [6]. In this issue, we introduce two respective original studies investigating its diagnostic availability for assessing liver fibrosis. The authors reported interesting results of comparison between M2BPGi and other serologic markers, transient elastography, and various scoring systems [3, 7]. M2BPGi is on the status of surrogate marker, which cannot fully substitute for liver biopsy; however, based on continuous efforts for finding new blood markers and promoting their diagnostic efficacy, we carefully hope that the new era for non-invasive assessment of liver fibrosis towards liquid biopsy might be realized in the field of liver diseases in the near future [4].

Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion

Potential of Mac‐2‐binding protein glycan isomer as a new therapeutic target in pancreatic cancer

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis

Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients

O1 Elevated Expression Level of Capillary Morphogenesis Gene 2 in Pancreatic Ductal Adenocarcinoma Cell is Associated with Distant Metastasis and Poor Prognosis

Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role

Prognostic and diagnostic value of circulating IGFBP2 in pancreatic cancer

Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases

Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis

Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics

High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma

Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer

Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis

Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma

Macc1: A Potential Molecule Associated With Pancreatic Cancer Metastasis And Chemoresistance

High Mobility Group AT-hook 2 and C-Myc As Potential Prognostic Factors in Pancreatic Ductal Adenocarcinoma

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma

GDF15 and LCN2 for early detection and prognosis of pancreatic cancer

Serum N-Glycome analysis reveals pancreatic cancer disease signatures

A Potential Biomarker to Differentiate Pancreatic Ductal Adenocarcinoma from Pancreatic Benign Lesions and Predict Vascular Invasion